## Mirtazapine D3

Cat. No.:	HY-B0352S		
CAS No.:	1216678-68-0		
Molecular Formula:	$C_{17}H_{16}D_{3}N_{3}$		
Molecular Weight:	268.37		
Target:	5-HT Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

## SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	3.7262 mL	18.6310 mL	37.2620 ml	
		5 mM	0.7452 mL	3.7262 mL	7.4524 mL	
		10 mM	0.3726 mL	1.8631 mL	3.7262 mL	
	Please refer to the sc	lubility information to select the app	propriate solvent.			
vo	Solubility: ≥ 2.5 m 2. Add each solvent	d each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline ubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution d each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) ubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution				
		Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution				

BIOLOGICAL ACTIVITY			
Description	Mirtazapine-d <sub>3</sub> is a deuterium labeled Mirtazapine. Mirtazapine is a 5-HT receptor inhibitor. Mirtazapine is a potent and orally active noradrenergic and specific serotonergic antidepressant (NaSSA) agent by blocking 5-HT2 and 5-HT3 receptors[1].		
IC <sub>50</sub> & Target	5-HT <sub>2</sub> Receptor	5-HT <sub>3</sub> Receptor	
In Vivo	Mirtazapine (intraperitoneal i	njection; 10–50 mg/Kg; 14 days) treatment normalizes heart rate, breath rate, anxiety levels	



D D

D

	pping behavior observed in MeCP2-null mice, leading to improved phenotypic score <sup>[2]</sup> . ently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	MeCP2 null mice <sup>[2]</sup>
Dosage:	10-50 mg/Kg
Administration:	Intraperitoneal injection; 10-50 mg/Kg; 14 days
Result:	Restored the thickness of MeCP2-null mice somatosensory cortex, especially of layers II-II and VI.

## REFERENCES

[1]. Anttila, S.A. and E.V. Leinonen, A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev, 2001. 7(3): p. 249-64.

[2]. Kooyman AR, et al. Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology. 1994 Mar-Apr;33(3-4):501-7.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA